Develops and sells medicines for serious diseases, including neurological and cardiometabolic conditions.
10-K for FY2025, filed Feb 26, 2026
The largest source is partner-funded research and collaboration activity: partners pay as Ionis performs research, when licenses are delivered and when certain milestones are achieved; medicine sales and royalties from partner sales also contribute.
10-K for FY2025, filed Feb 26, 2026We recognize collaborative agreement revenue in one of two ways, over time or at a point in time. We recognize revenue over time when we…View ↗
We enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration…View ↗
Milestone payments: We include variable consideration in the transaction price when it is probable. We typically include milestone payments…View ↗
We recognize revenue from product sales when the customer obtains control of our product in the amount of the transaction price, which is…View ↗
We recognize royalty revenue in the period in which the counterparty sells the related product and recognizes the related revenue, which in…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$943.7M
10-K for FY2025, filed Feb 26, 2026
$943.7M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Sales, Net
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
12%
FY2022: 5.1%
|
Product Sales, Net, FY2025
$115.3M Sources
|
Sold outright |
|
Royalty Revenue
Licensed
10-K for FY2025, filed Feb 26, 2026 |
30% |
Royalty Revenue, FY2025
$285.5M Sources
|
Licensed |
|
Other Commercial Revenue
|
3.7%
FY2022: 10%
|
Other Commercial Revenue, FY2025
$35M Sources
|
|
|
Commercial Revenue
|
46%
FY2022: 52%
|
Commercial Revenue, FY2025
$435.8M Sources
|
|
|
Collaborative Agreement Revenue
Mix
10-K for FY2025, filed Feb 26, 2026 |
49%
FY2022: 35%
|
Collaborative Agreement Revenue, FY2025
$465.8M Sources
|
Mix |
|
WAINUA Joint Development Revenue
Recurring
|
4.5%
FY2022: 13%
|
WAINUA Joint Development Revenue, FY2025
$42.1M Sources
|
Recurring |
|
Research and Development Revenue
Mix
10-K for FY2025, filed Feb 26, 2026 |
54%
FY2022: 48%
|
Research and Development Revenue, FY2025
$507.9M Sources
|
Mix |
Ionis sells TRYNGOLZA and DAWNZERA itself in the U.S.; AstraZeneca and Biogen commercialize WAINUA and SPINRAZA, while Sobi distributes WAYLIVRA in Europe and PTC commercializes it in Brazil. Development partners license Ionis technology and work with it on research.
10-K for FY2025, filed Feb 26, 2026TRYNGOLZA is approved in the United States, or U.S., as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia…View ↗
DAWNZERA is approved in the U.S. for prophylaxis to prevent attacks of hereditary angioedema, or HAE, in adult and pediatric patients 12…View ↗
WAINUA is approved in the U.S., EU, China and numerous other countries for the treatment of the polyneuropathy of hereditary…View ↗
SPINRAZA is a global market leader for the treatment of patients with spinal muscular atrophy, or SMA. Our partner, Biogen, is responsible…View ↗
WAYLIVRA is approved in the EU and Brazil as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk for…View ↗
We enter into collaboration agreements to license and sell our technology on an exclusive or non-exclusive basis. Our collaboration…View ↗
No. It lost $381.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$110MView ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
Open tableView ↗
8-K, filed Nov 9, 2026
– TRYNGOLZA® (olezarsen) 2026 product sales guidance lowered as sHTG launch ramps more gradually than expected reflecting early dynamics of…View ↗
8-K, filed Oct 21, 2026
On October 20, 2026, Ionis reported that its partner, GSK, announced that the FDA has approved HIBSAGO™ (bepirovirsen) for the treatment of…View ↗
8-K, filed Sep 4, 2026
- ZANVASTRO marks Ionis’ first independent launch from its industry-leading neurology pipeline and second independent launch this year –View ↗
Growing. Revenue grew 16% in 4 years, from $810.5M in FY2021 to $943.7M in FY2025, about 4% a year.
More marketed medicines and direct launches
The older report described SPINRAZA, TEGSEDI and WAYLIVRA as marketed, with eplontersen and tofersen still in development; the latest describes additional marketed medicines and independent Ionis sales of TRYNGOLZA and DAWNZERA alongside partner-led commercialization.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Feb 26, 2026We currently have three marketed medicines: SPINRAZA, TEGSEDI and WAYLIVRA. Additionally, we have two medicines that will add to our…View ↗
TEGSEDI is a once weekly, self-administered subcutaneous medicine approved in the U.S., Europe, Canada and Brazil for the treatment of…View ↗
WAYLIVRA is a once weekly, self-administered, subcutaneous medicine that received conditional marketing authorization in May 2019 from the…View ↗
In the last year, we delivered on our strategy to create accelerating value for all our stakeholders. With two independent commercial…View ↗
TRYNGOLZA is approved in the United States, or U.S., as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia…View ↗
DAWNZERA is approved in the U.S. for prophylaxis to prevent attacks of hereditary angioedema, or HAE, in adult and pediatric patients 12…View ↗
Competes with Arrowhead Pharmaceuticals, Roche, NorthSea Therapeutics, Eli Lilly, Takeda, BioCryst, CSL Behring, Pharvaris, Intellia, ADARx, Alnylam, Pfizer, BridgeBio, Novo Nordisk, Novartis, Ultragenyx, Neuren, Gilead Sciences, Arbutus Biopharma, and Barinthus Bio
10-K for FY2025, filed Feb 26, 2026Medicine Company Medicine Description(1) Phase(1) Route of Administration(1) Redemplo (Plozasiran) Arrowhead Pharmaceuticals Targets…View ↗
Loading...